Stock Financial Ratios, Dividends, Split History

MOH / Molina Healthcare, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)6,596.59
Enterprise Value ($M)4,324.99
Book Value ($M)1,337.00
Book Value / Share22.39
Price / Book4.25
NCAV ($M)377.00
NCAV / Share6.31
Price / NCAV10.61
Share Statistics
Weighted Average Number Of Shares Outstanding Basic 56,000,000
Common Shares Outstanding 59,727,000
Preferred Stock Shares Outstanding 0
Weighted Average Number Of Diluted Shares Outstanding 56,000,000
Common Stock Shares Outstanding 60,000,000
Scoring Models
Piotroski F-Score2.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.18
Return on Assets (ROA)-0.07
Return on Equity (ROE)-0.31
Balance Sheet (mrq) ($M)
Quick Ration/a
Current Ratio1.35
Income Statement (mra) ($M)
Health Care Organization Premium Revenue18,854,000,000.00
Management Fees Revenue0.00
Technology Services Revenue521,000,000.00
Administrative Services Revenue50,000,000.00
Health Care Organization Insurer Fee Revenue0.00
Health Care Organization Other Revenue0.00
Operating Income-555.00
Net Income-512.00
Earnings Per Share Diluted-9.07
Earnings Per Share Basic-9.07
Cash Flow Statement (mra) ($M)
Cash From Operations804.00
Cash from Investing-1,073.00
Cash from Financing-1,073.00
Identifiers and Descriptors
Central Index Key (CIK)1179929
Related CUSIPS
60855R950 60855R900

Split History

Stock splits are used by Molina Healthcare, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

UnitedHealth's (UNH) Q2 Earnings Beat, 2018 Guidance Up

16h zacks
UnitedHealth Group Inc.’s (UNH - Free Report) second-quarter 2018 earnings of $3.14 per share surpassed the Zacks Consensus Estimate of $3.03. Also, the reported figure was up 28% year over year. (3-0)

Will Higher Revenues Aid UnitedHealth's (UNH) Q2 Earnings?

2018-07-13 zacks
UnitedHealth Group Inc. (UNH - Free Report) is scheduled to release second-quarter earnings results on Jul 17, 2018, before the opening bell. The company is anticipated to deliver a positive earnings surprise. (3-0)

Humana (HUM) Jointly Buys Curo, Boosts Medicare Business

2018-07-12 zacks
Humana Inc. (HUM - Free Report) recently announced that it has completed the joint acquisition of Curo Health Services (Curo) with Welsh, Carson, Anderson & Stowe (“WCAS”), collectively known as the Consortium. The transaction was approximately valued at $1.4 billion. Humana will own a 40% minority interest in this deal. A nationwide leading hospice operator, Curo caters to patients at 245 locations across 22 states. (1-0)

The Zacks Analyst Blog Highlights: Micron Technology, ArcBest, Marathon Oil, Azure Power Global and Molina Healthcare

2018-07-10 zacks
Chicago, IL – July 10, 2018 – announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Micron Technology Inc. (MU - Free Report) , ArcBest Corp. (ARCB - Free Report) , Marathon Oil Corp. (MRO - Free Report) , Azure Power Global Ltd. (5-1)

UnitedHealth's Unit to Provide Better Care in North Carolina

2018-07-10 zacks
UnitedHealth Group Inc.‘s (UNH - Free Report) subsidiary UnitedHealthcare has collaborated with Community Care Physician Network LLC (“CCPN”) for creating a new Advanced Care Medical Home and care management network relationship. With this agreement, North Carolina Medicaid beneficiaries get the right to access CCPN’s 2,200 independent primary care providers in counties across the state under the new managed care system, that will be launched in 2019. (3-0)

CUSIP: 60855R100